Clinical Trials Directory

Trials / Sponsors / Beacon Therapeutics

Beacon Therapeutics

Industry · 13 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in M
X-Linked Retinitis Pigmentosa (XLRP)
Phase 22025-09-10
Active Not RecruitingA Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participan
X-Linked Retinitis Pigmentosa
Phase 2 / Phase 32024-03-14
Enrolling By InvitationA Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR
X-Linked Retinitis Pigmentosa
Phase 22023-11-14
Active Not RecruitingA Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mut
X-Linked Retinitis Pigmentosa
Phase 22021-04-13
Active Not RecruitingSafety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutati
X-Linked Retinitis Pigmentosa
Phase 1 / Phase 22018-04-16
CompletedClinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)
X-Linked Retinitis Pigmentosa
—2017-12-01
Active Not RecruitingSafety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
Achromatopsia
Phase 1 / Phase 22017-08-03
Active Not RecruitingSafety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
Achromatopsia
Phase 1 / Phase 22016-04-11
CompletedSafety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
X-linked Retinoschisis
Phase 1 / Phase 22015-05-01
CompletedClinical and Genetic Characterization of Individuals With Achromatopsia
Achromatopsia
—2013-06-01
CompletedClinical Evaluation of Patients With X-linked Retinoschisis
X-linked Retinoschisis, XLRS
—2012-11-01
CompletedSafety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency
Phase 22010-06-01
CompletedPhase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Leber Congenital Amaurosis
Phase 1 / Phase 22009-06-17